Access to rifapentine for TB webinar

Despite the development of new drugs, and trials to support more effective treatment regimens for TB, cure cannot be achieved without access to medicines. Drug pricing, access policies and patent issues are often responsible for inequalities in getting access to lifesaving medicines to people that need most. Our previous webinar gave an overview of these issues. In our next webinar in this series we will explore, in-depth, access to Rifapentine. Two talks from experts in the field will cover the evidence behind rifapentine's use in TB and unpack specific barriers to its use. This will be followed by discussions with the audience. More information (and the video link when available) here